Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://endpts.com/fda-expands-label-for-nasal-spray-to-treat-chronic-sinus-infections/
https://www.globenewswire.com//news-release/2024/03/15/2847277/0/en/XHANCE-Approved-by-FDA-as-First-and-Only-Medication-Indicated-for-Treatment-of-Adults-with-Chronic-Rhinosinusitis-without-Nasal-Polyps.html
https://www.globenewswire.com//news-release/2024/03/07/2842112/0/en/Optinose-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Operational-Highlights.html
https://www.globenewswire.com//news-release/2024/02/29/2838451/0/en/Optinose-Announces-Reporting-Date-for-Fourth-Quarter-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/01/18/2811788/0/en/Optinose-Announces-the-Publication-of-ReOpen-Phase-3-Clinical-Trial-Program-Evaluating-XHANCE-in-the-Journal-of-Allergy-and-Clinical-Immunology-In-Practice.html
https://www.biospace.com/article/releases/optinose-announces-3-month-extension-of-fda-review-period-for-the-supplemental-new-drug-application-for-xhance/
https://www.globenewswire.com/news-release/2023/12/06/2791632/0/en/Optinose-Announces-3-Month-Extension-of-FDA-Review-Period-for-the-Supplemental-New-Drug-Application-for-XHANCE.html
https://www.globenewswire.com//news-release/2023/11/22/2784826/0/en/Optinose-to-Present-at-the-35th-Annual-Piper-Sandler-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/11/09/2777182/0/en/Optinose-Reports-Third-Quarter-2023-Financial-Results-and-Operational-Updates.html
https://www.globenewswire.com//news-release/2023/10/27/2768376/0/en/Optinose-Announces-Reporting-Date-for-Third-Quarter-2023-Financial-Results.html